We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.05 | -0.11% | 43.45 | 43.64 | 43.175 | 43.63 | 2,045,663 | 22:13:59 |
From May 2019 to May 2024
LONDON--GlaxoSmithKline PLC (GSK.LN) Tuesday said the Salford lung study for chronic obstructive pulmonary disease, in collaboration with Innoviva Inc. (INVA), has had positive headline results.
The FTSE-100 healthcare company said the study showed that Relvar Ellipta achieved a superior reduction in exacerbations, compared with the usual care, in patients with COPD in an everyday clinical-practice setting. Study analyses are ongoing, the company said.
Shares at 1000 GMT up 5.50 pence, or 0.4%, at 1443.50 pence valuing the company at 70.32 billion pounds ($101.94 billion).
Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga
(END) Dow Jones Newswires
May 24, 2016 06:27 ET (10:27 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
